Two developments from the last weeks say a lot about where the vaginal microbiome category is heading.
- Juno Bio raised $3.8 million and opened its own CLIA-certified sequencing lab - positioning itself not as a direct-to-consumer wellness brand but as clinical infrastructure other providers and researchers can build on.
- And Daye published research, with academic partners, arguing that the vaginal microbiome should be folded into cervical cancer risk models.
Neither is a splashy consumer launch. Both are bids for clinical legitimacy. Taken together, they seem to mark a category graduating from wellness curiosity into something closer to medical infrastructure.
So today I feel like t’s worth stepping back to map how the vaginal microbiome diagnostics and care got here - and what still stands between them and mainstream clinical adoption.
Why the Vaginal Microbiome Matters
The vaginal microbiome is the community of bacteria and other microorganisms that live in the vagina. A microbiome dominated by Lactobacillus - particularly Lactobacillus crispatus - is generally associated with protective, healthy states, while a more diverse, anaerobe-rich environment (dysbiosis) is linked to a range of negative outcomes.
Research over the past decade has connected the vaginal microbiome to fertility and IVF success, pregnancy outcomes including preterm birth, susceptibility to STIs and HPV persistence, and the everyday burden of recurrent infections like bacterial vaginosis and yeast infections.
As microbiome scientist Kimberly Capone explained in a conversation with us a while ago, the old assumption that a “healthy” vaginal microbiome simply meant Lactobacillus dominance turns out to be far more nuanced - the composition, diversity, and specific strains all matter, and they shift across the menstrual cycle, pregnancy, and menopause. And that complexity is exactly why simple, single-snapshot testing has historically fallen short, and why sequencing-based approaches have become the technical foundation of the category.
The clinical need is real. The standard of care for diagnosing vaginal infections - the wet mount, vaginal pH, and the “whiff test” - has remained largely unchanged for decades, and study after study finds it unreliable. Peer-reviewed estimates put the misdiagnosis rate for vaginitis at 30 to 50% or higher, and research consistently shows providers frequently skip even the basic office tests.
That gap between how common these conditions are and how poorly they’re diagnosed is the opening the microbiome companies are building into.
Phase One: At-Home Testing at Scale
The first commercial wave brought vaginal microbiome testing out of the lab and into the home. Evvy, founded in New York, built the highest-profile consumer brand in the U.S. - a metagenomic sequencing test from a single at-home swab, paired with treatment pathways and coaching. The company has raised around $19 million to date and built what it describes as the world’s largest vaginal microbiome dataset, north of 100,000 tests. Juno Bio built a parallel at-home offering in the UK and US, selling more than 20,000 tests and accumulating its own large data repository.
Others approached collection differently. Daye for example built its testing around a diagnostic tampon, a collection method it argues is both more comfortable and able to capture a richer sample.
A broader field of players - Tiny Health, Fertilysis, Varinos, and others - has formed around specific niches from infant and family microbiome health to fertility-clinic applications.
The shared model of this phase: Sequence the microbiome, return a report, connect the user to treatment or coaching.
Phase Two: Data, AI, and Fertility Applications
As testing volume grew, the datasets themselves became valuable - and companies began building intelligence layers on top of them. In early 2026, Evvy launched EvvyAI, an AI advisor trained on its 100,000+ tests and built specifically on female-body data - a direct response to the finding that general-purpose AI models perform poorly on women’s health questions. The pitch is that a proprietary, condition-specific dataset produces guidance that generic models can’t.
The category also began moving from “what’s wrong” toward “what does this predict.” Evvy added fertility insights to its test, translating microbiome composition into signals relevant to conception, IVF outcomes, and pregnancy loss - drawing on research linking specific bacteria to embryo implantation and preterm birth.
This is where the microbiome starts to look less like a wellness readout and more like a biomarker.
Phase Three: The Clinical Frontier
Which brings us back to last week. The two developments represent the category’s most serious push yet toward clinical legitimacy, from two different directions.
Juno Bio’s move is about infrastructure. By opening its own CLIA-certified sequencing lab - built specifically for women’s health - the company is positioning itself as the data-and-diagnostics layer beneath the category rather than a consumer brand competing for swab sales. Its new test analyzes roughly 10,000 bacteria and fungi plus common STIs from a single sample, and the company has moved into pharmaceutical R&D partnerships and telehealth integrations. The backing is telling: The Illumina Accelerator (sequencing’s biggest name). The bet here is that whoever builds the clinical-grade reference infrastructure becomes foundational to everyone else.
Daye’s move is about evidence. Its paper, written with researchers at UCL, Queen Mary University of London, and the London School of Hygiene and Tropical Medicine, argues that cervical cancer screening is missing a signal it could already be measuring. The biology is well established - Lactobacillus-dominant microbiomes appear protective, while dysbiotic ones are associated with HPV persistence and higher-grade disease - yet no cervical cancer risk model in clinical use incorporates the microbiome at all.
The practical hook: Daye’s tampon can read the microbiome from the same self-collected sample already taken for HPV screening, adding essentially no burden. The deeper argument is a reframing - from asking whether HPV is present, to asking whether the vaginal environment is one in which the virus can persist.
What Still Stands in the Way
For all the momentum, real obstacles remain between the microbiome and routine clinical use. The evidence base, while growing, is still maturing - associations between microbiome states and outcomes are well documented, but validated, prospective risk models that clinicians can act on are largely still to come.
Reimbursement is thin: Most of these tests are consumer-pay, which limits reach to those who can afford it. And clinical inertia is powerful - a standard of care built on the microscope and the pH strip has persisted for decades precisely because changing entrenched clinical workflows is slow, even when the existing tools underperform.
There’s also a strategic question the two paths raise. Juno is betting on becoming infrastructure; Evvy has built scale and a dataset moat on the consumer side; Daye is pushing the research-and-diagnostics frontier.
It’s not yet clear whether this becomes a market of specialized layers that coexist, or whether the winners are the ones that control both the data and the clinical relationship. What is clear is that the era of the vaginal microbiome as a novelty wellness swab is ending.
The vaginal microbiome has spent the past several years proving it can be measured, that consumers want the information, and that the data has value. The next phase is harder: Proving it belongs in clinical decision-making, and building the evidence, infrastructure, and access to get it there. Last week’s developments suggest the category has decided that’s the fight worth having - and that the wellness swab was only ever the beginning.
